CRM successfully conduct the Research Proposal Writing Workshop


We would like to thank all our participants for the Research Proposal Writing Workshop by Dr. Masliza Mahmod! We hope all of you had gathered as much knowledge from Dr. Masliza these past 2 days.

Our heartiest appreciation to Dr. Mazliza Mahmod for accepting our invitation to conduct the workshop here with us. We thank you!

Not to forget our guest speakers Dr. Mahmoud Danaee & Dr. Ivy Chung from University of Malaya contributing your time to be with us.

Congratulations Oncology Department in HKL!

Congratulations! to Dr. Malwinder Singh Sandhu & his team over in Hospital Kuala Lumpur as the first recruiter globally for a breast cancer study on February 2019. Thank you team for making Malaysia #1!

Press Statement DG of Health 29 May 2019 – 72nd World Health Assembly

Resolution On ‘Improving the Transparency of Markets for Medicines, Vaccines, and Other Health Products’

The Ministry of Health Malaysia (MOH) welcomes a successful resolution laid out on ‘Improving the Transparency of Markets for Medicines, Vaccines, and Other Health Products’ at the World Health Organization 72nd World Health Assembly (WHA) held on 20th to 28th May 2019, Geneva. This was after intense negotiations with Member States to agree with the draft resolution proposed by Italy. Malaysia is one of the initial six (6) co-sponsors (Greece, Italy, Malaysia, Serbia, Spain and Uganda) to the resolution that gradually gained support from nineteen (19) countries (Andorra, Brazil, Egypt, Eswatini, Greece, India, Italy, Kenya, Luxembourg, Malaysia, Malta, Portugal, Russian Federation, Serbia, Slovenia, South Africa, Spain, Sri Lanka and Uganda).

Access to medicines and vaccines is a concern shared by all regions. Malaysia strongly supports the initiative to encourage more transparency and improved policies and actions to ensure fairer pricing and reduction of out-of-pocket payments. The Ministry believes that a sustainable fairer pricing system is needed for both health systems and pharmaceutical industries. This landmark agreement is a first step towards a more open dialogue about price transparency to improve access to medicines.

The resolution urged Member States to undertake measures to publicly share information on prices and reimbursement cost of medicines and improve the public reporting of the patent status information and marketing approval status, among others. A greater price transparency will add as another tool that will change the way drug prices are negotiated by governments and national health systems to fight against the rising cost of healthcare. The Ministry believes this move will help strengthen our government’s negotiating position and enhance our ability to obtain more affordable medicines for our people.

The Ministry has put in various measure to increase access to medicines such as pool procurement between inter-ministries, active price negotiations, as well as involvement in research and development (R&D) through partnership by Clinical Research Malaysia (CRM) with R&D institutions such as Drugs for Neglected Diseases initiative (DNDi). We will continue our efforts to improve universal access to medicines and affordable medicines, as one of the components in the National Medicines Policy, where the cost of drugs should not be a barrier for Malaysians to get quality health care. This is in line with our commitment of Universal Health Coverage (UHC), in which people’s interest come first to ensure universal access of medicine to the Malaysian people.

Our decision and motivation to support this resolution has always been our patients and the people of Malaysia. We hope to see more positive steps and policies in the near future to see the transparency resolution come to fruition.

Datuk Dr Noor Hisham bin Abdullah
Director General of Health
29 May 2019


[VIDEO] MRVR (Medical Rehabilitation Virtual Reality)

Congratulations Dr. Chan Lee Gaik & Hospital Umum Sarawak study team!

Congratulations Dr. Chan Lee Gaik and Hospital Umum Sarawak study team for recruiting the first subject in Malaysia for Peads Influenza study on 13 March and achieving extended recruitment target on 30 April.

Double Joy for Hospital Miri on Patient Recruitment

Double joy for Hospital Miri!

We would like to congratulate Dato’ Dr. Fam Tem Lom and Dr. Louise Ngu, and their study team for being the first in Malaysia to recruit patients for Influenza A (on 15 March) & Peads RSV (on 7 May) study respectively.

We are truly proud of these achievements and hope for more great news from Hospital Miri.


Dato’ Dr. Fam with his study team.

Master of Health Research Ethics (MOHRE) Programme – University of Malaya

The University of Malaya together with the Johns Hopkins Berman Institute of Bioethics have developed the Master of Health Research Ethics (MOHRE) Programme which is funded by the US National Institute of Health.

The development of this programme draws on the expertise of bioethicists and educationist from Johns Hopkins University and a multidisciplinary group of faculty members from UM in the field of medicine, law, and education. This one-year programme provides an excellent opportunity to learn about research ethical issues in the field of health and medicine through theories and practicum.

Graduates of the programme will have the opportunity to explore careers related to health research ethics such as research ethics committee member, university, academician or lecturer, a researcher in health institutions, manager of clinical research centers, an executive in ethics accreditation body and policy-makers in a government agency. Ten scholarships are provided for eligible candidates.


The application deadline is on 31 May every year.


For more information about the Programme, please visit our website: If you have any queries, please email to

Investigators Dialogue 2019 – Thank You Investigators!

KUALA LUMPUR, 25 April 2019 – We had the CRM Investigator Dialogue 2019, a platform to discuss relevant matters in conducting Sponsored Research.

We invited Ms Yam Pei Ching (NPRA), Dr Hjh Salina Abdul Aziz (MREC), Dr Hjh Rosaida Hj Md Said (Investigator, Hospital Ampang) and Ms SuLyn Yip (Novotech) to give a talk and updates on their respective areas.

Special thanks to Dato’ Dr Goh Pik Pin, Director of Clinical Research Centre Malaysia for her welcoming speech.

Last but not least, a big thank you to all investigators for your time and thoughts given for this year Investigator Dialogue.


Thank You! – Industry Dialogue 2019/1

Its the first CRM Industry Dialogue for 2019!

CRM Industry Dialogue provides an avenue for Pharmaceutical companies (sponsors) and CROs to directly convey any issues, suggestions or opinions that they may have to CRM. Besides strengthening cooperation and networking between all parties, CRM also takes the opportunity to update the clinical research industry on local laws, guidelines and regulations. By bringing together these industry players, CRM uses this platform to connect with them and provide upates on its current and future activities.

Guest Speakers
We would to thank our guest speakers Ms. Yip Su Lyn (Country Manager, Novotech), Dr. Zaril Harza bin Zakaria (Deputy Director, Centre for Investigational New Product, NPRA) and Dr. Hjh Salina Abdul Aziz (Chairperson, MREC) for sharing important updates with us today.

Dialogue Session
We invited Dr Hjh Salina Abd Aziz (Chairperson, MREC), Dr Zaril Harza Zakari (Deputy Director, NPRA), Puan Aidahwaty (Director Technical Evaluation, MDA), Mr Lau Thye Mun (Deputy Director, Royal Malaysian Customs Department) and Mr Ewe Kheng Huat (Executive Director, PhAMA) to have a dialogue session with the industry players.

Our humble gratitude to all.


ResMed Support for Investigator-Initiated Research

ResMed changes lives with award-winning medical devices and cutting-edge cloud-based software applications that diagnose, treat and manage sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD) and other chronic respiratory diseases. ResMed is a global leader in connected care, with millions of patients remotely monitored every day. Our team is committed to creating the world’s best tech-driven medical device company – improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 100 countries. Read more